Navigation Links
RQx Pharmaceuticals and Genentech Enter Drug Discovery Collaboration to Develop Novel Drug Compounds
Date:2/12/2013

LA JOLLA, Calif., Feb. 12, 2013 /PRNewswire/ -- RQx Pharmaceuticals, Inc. today announced that it has entered into a drug discovery collaboration with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), for the discovery and development of novel drug compounds for an undisclosed target. Under the terms of the agreement, RQx will receive an up-front payment and is eligible to receive research and development milestone payments totaling $111 million.  In addition, RQx is eligible to receive royalties on sales of products resulting from the collaboration.

"We have made tremendous progress at RQx since the company's founding two years ago, and we are pleased to be moving forward in partnership with Genentech to bring new drugs to market," said Court Turner, CEO of RQx and venture partner at Avalon Ventures.

RQx Pharmaceuticals was founded by Avalon Ventures in 2010 with Floyd Romesberg , Ph.D., a professor at The Scripps Research Institute (La Jolla, CA) and two former graduate students of the Romesberg Lab.  Avalon Ventures formed the company, then seeded and led the Company's Series A financing, which also included an investment from Correlation Ventures. 

"We see a unique opportunity to apply Genentech's expertise in drug discovery and development with the innovation and focus of RQx, to develop a new class of novel drug compounds," said James Sabry , senior vice president of partnering at Genentech.

About RxQ Pharmaceuticals, Inc.

RQx Pharmaceuticals is a biopharmaceutical company developing broad-spectrum small molecule antibiotics to combat serious life threatening infections, including those caused by multi drug-resistant Gram-negative bacteria. To address the growing threat of MDR bacteria, RQx is developing novel, first-in-class antibiotics that evade the current abundance of antibiotic resistance mechanisms, which are now common across the globe.  RQx is inspired by the synergies possible when combining naturally produced antibiotics with modern medical chemistry capabilities and is focused on identifying ideal target/inhibitor combinations to deliver a pipeline of novel antibiotic candidates.


'/>"/>
SOURCE RQx Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Vanda Pharmaceuticals Reports Fourth Quarter 2012 and Full Year 2012 Results
2. Jazz Pharmaceuticals To Report 2012 Fourth Quarter And Full Year Financial Results On February 26, 2013
3. DelMar Pharmaceuticals Announces $1.0 Million Third Closing in Private Placement
4. Perrigo Company Acquires U.K.-based Rosemont Pharmaceuticals Ltd. For Approximately £180 Million Or $283 Million
5. Inovio Pharmaceuticals, Inc. Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
6. Imprimis Pharmaceuticals Announces Pricing of Public Offering of 1,840,000 Shares of Common Stock
7. Anthera Pharmaceuticals to Present at the 2013 Leerink Global Healthcare Conference
8. Avanir Pharmaceuticals Reports Fiscal 2013 First Quarter Financial And Business Results
9. Shares of Oramed Pharmaceuticals Are Approved for Listing on the Nasdaq Capital Market
10. Avanir Pharmaceuticals Announces Positive Interim Data From Pharmacokinetic Study With Next Generation Compound AVP-786
11. Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Fiscal Year 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... 2016 Research and ... Systemic Lupus Erythematosus Market and Competitive Landscape ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Systemic Lupus Erythematosus Market and Competitive Landscape ... Systemic Lupus Erythematosus pipeline products, Systemic Lupus ...
(Date:5/4/2016)... Israel , May 4, 2016 ... that BiondVax,s CEO, Dr. Ron Babecoff , will be ... New York City . On Thursday, May ... 2016, a conference presented by Joseph Gunner & ... The BiondVax presentation that Dr. Babecoff will be using ...
(Date:5/4/2016)... New Jersey , May 4, 2016 ... its successful completion of an alternative public offering (APO). ... wholly owned operating company, Valeritas, Inc. and a private ... common stock at $5.00 per share. Under ... on May 3, 2016, Valeritas Holdings, Inc. will trade ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... May 05, 2016 , ... An essential tool for ... and certain Canadian provinces is now available from the International Association of Industrial ... , The report, Workers’ Compensation Laws as of January 1, 2016, ...
(Date:5/5/2016)... ... 05, 2016 , ... Tim Dieter has announced the latest ... Dubuque, IA. The current campaign fundraises for Veteran’s Freedom Center on behalf of ... Freedom Center may now be made here: http://www.veteransfreedomcenter.com/donate/ . , Veteran’s Freedom ...
(Date:5/5/2016)... ... ... Dr. Benjamin Stong of Kalos Facial Plastic Surgery, LLC in Atlanta, Georgia proudly ... certified and the only facial plastic surgeon in Atlanta to offer Micro-droplet Fat ... stem cells can be used to provide stabilization to hair transplant results or they ...
(Date:5/5/2016)... York) , ... (PRWEB) May 05, 2016 , ... ... talent acquisition startup, HireNurses, on the eve of National Nurses Week (May ... nurses and healthcare employers. With their enrollment into the Talent Tech Lab Virtual Incubation ...
(Date:5/5/2016)... Rochester, NY (PRWEB) , ... May 05, 2016 ... ... app is now available for iOS and Android devices. VisualDx is the ... expanded to include diagnostic support across general medicine. The system speeds diagnosis, ...
Breaking Medicine News(10 mins):